Romania's drug market expenditure was RON8.42bn (US$3.05bn) in 2009. Out of the 20 Central and Eastern European (CEE) countries analysed by BMI, this figure positions Romania seventh in terms of market size, However, per-capita spending on pharmaceuticals of just US$141.9 in 2009 places Romania 14th in the region for this indicator and reflects the limited funding available for high-value innovative drugs. The long-term prospects for Romania's attractiveness to pharmaceutical companies are dependent on the implementation of proposals for healthcare reform, which is expected to be completed by the end of 2010. While there are significant downsides to the proposals, BMI believes they are necessary to ensure the long-term financial sustainability of the healthcare in Romania, which will ultimately benefit the pharmaceutical companies operating in the country. While Romania's predominantly publicly-financed healthcare service has been chronically underfunded for many years, action will be forced as a result of extensive budget deficits in the healthcare system that have built up over the last two years. Worryingly, the last trimester of 2009 was financed with credits from the 2010 budget, and many had feared that the entire 2010 budget would only last until July. While Romania's healthcare system faces immense challenges in the short to medium term, it is unlikely that the provision of medical services will collapse due to budget shortfalls. In January 2010, a source at the Romanian College of Physicians reported to the Canadian Medical Association Journal (CMAJ) that funding for the healthcare budget would only last until mid 2010, and that the system was facing imminent collapse. At the time, Romania's minister of health, Atilla Cseke, did not dispute the suggestion. Paradoxically, the fact the country's healthcare system has been so chronically underfunded over the last decade makes it less likely that continued funding shortfalls will push the system over the edge. In the short term, Romania's health minister hopes total collapse will be prevented with more efficient use of existing funds, the elimination of waste and introduction of co-payments. However, in the long term BMI believes that only more substantial funding changes will avert failure in the medical services sector. Reduced revenues from the country's National Health Insurance Fund (CNAS), which is primarily financed by wage contributions, have been hit extensively as Romania went through a recession in 2009 and suffered from higher levels of unemployment.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Romania Pharmaceuticals and Healthcare Report Q4 2010
Published on September 2010
Report Summary
Romania's drug market expenditure was RON8.42bn (US$3.05bn) in 2009. Out of the 20 Central and Eastern European (CEE)
countries analysed by BMI, this figure positions Romania seventh in terms of market size, However, per-capita spending on
pharmaceuticals of just US$141.9 in 2009 places Romania 14th in the region for this indicator and reflects the limited funding
available for high-value innovative drugs.
The long-term prospects for Romania's attractiveness to pharmaceutical companies are dependent on the implementation of
proposals for healthcare reform, which is expected to be completed by the end of 2010. While there are significant downsides to the
proposals, BMI believes they are necessary to ensure the long-term financial sustainability of the healthcare in Romania, which will
ultimately benefit the pharmaceutical companies operating in the country. While Romania's predominantly publicly-financed
healthcare service has been chronically underfunded for many years, action will be forced as a result of extensive budget deficits in
the healthcare system that have built up over the last two years. Worryingly, the last trimester of 2009 was financed with credits from
the 2010 budget, and many had feared that the entire 2010 budget would only last until July.
While Romania's healthcare system faces immense challenges in the short to medium term, it is unlikely that the provision of medical
services will collapse due to budget shortfalls. In January 2010, a source at the Romanian College of Physicians reported to the
Canadian Medical Association Journal (CMAJ) that funding for the healthcare budget would only last until mid 2010, and that the
system was facing imminent collapse. At the time, Romania's minister of health, Atilla Cseke, did not dispute the suggestion.
Paradoxically, the fact the country's healthcare system has been so chronically underfunded over the last decade makes it less likely
that continued funding shortfalls will push the system over the edge.
In the short term, Romania's health minister hopes total collapse will be prevented with more efficient use of existing funds, the
elimination of waste and introduction of co-payments. However, in the long term BMI believes that only more substantial funding
changes will avert failure in the medical services sector. Reduced revenues from the country's National Health Insurance Fund
(CNAS), which is primarily financed by wage contributions, have been hit extensively as Romania went through a recession in 2009
and suffered from higher levels of unemployment.
Table of Content
Executive Summary ... 5
SWOT Analysis .... 7
Romania Pharmaceuticals And Healthcare Industry SWOT ... 7
Romania Political SWOT 8
Romania Economic SWOT ..... 8
Romania Business Environment SWOT ...... 9
Pharmaceutical Business Environment Ratings .... 10
Table: Emerging Europe ' Regional Pharmaceuticals Business Environment Ratings, Q410 ...... 10
Rewards ... 11
Risks . 12
Romania ' Market Summary .. 14
Regulatory Regime ... 16
Romania Pharmaceuticals and Healthcare Report Q4 2010 Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Intellectual Property Issues . 17
Corruption ...... 18
Pricing Regime ...... 20
Table: Romania 'Distributor Margins...... 21
Table: Romania 'Pharmacy Margins 21
Reimbursement Regime . 22
Industry Developments... 25
Epidemiology .. 25
Table: Disease Burden In CEE ... 27
HIV Burden ..... 28
Table: HIV Prevalence In Romania ... 28
Healthcare Sector .. 29
Healthcare Sector Funding .. 33
Industry Forecast Scenario .... 35
Overall Market Forecast...... 35
Key Growth Factors ' Industry... 37
Macroeconomic Forecast Scenario ... 38
Table: Romania ' Economic Activity . 41
Prescription Drug Market Forecast ... 42
Patented Drug Market Forecast . 44
Generic Drug Market Forecast ... 46
OTC Medicine Market Forecast . 47
Pharmaceutical Trade Forecast . 49
Medical Device Market Forecast 51
Key Risks to BMI's Forecast Scenario ...... 53
Competitive Landscape .. 54
Pharmaceutical Industry ...... 54
Pharmaceutical Industry Developments ... 56
Wholesale Sector ... 58
Retail Sector ... 60
Company Monitor ..... 62
Indigenous Companies 62
Zentiva (Incorporating Sicomed) 62
Actavis Romania (Sindan) .... 66
Terapia-Ranbaxy ... 69
Antibiotice Iasi 72
Ozone Laboratories ...... 76
LaborMed Pharma . 78
Foreign Companies ..... 80
GlaxoSmithKline (Europharm) ... 80
Roche 84
Sanofi-Aventis . 86
Novartis ... 88
Pfizer 90
Krka .. 91
Merck & Co .... 93
Country Snapshot: Romania Demographic Data .... 94
Section 1: Population .... 94
Section 2: Education and Healthcare 95
Table: Vital Statistics, 2005-2030 ...... 95
Romania Pharmaceuticals and Healthcare Report Q4 2010 Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Section 3: Labour Market and Spending Power...... 96
Table: Employment Indicators, 2001-2006 ...... 96
Table: Consumer Expenditure, 2005-2010 (US$) ... 96
Table: Average Annual Wages, 2006-2010 ...... 97
BMI Methodology ..... 98
How We Generate Our Pharmaceutical Industry Forecasts . 98
Pharmaceuticals Business Environment Ratings .... 99
Risk/Reward Ratings Methodology .... 99
Ratings Overview ... 99
Table: Pharmaceutical Business Environment Indicators ...100
Weighting 101
Table: Weighting Of Components .....101
Sources ...101
Forecast Tables ...... 102
Romania Pharmaceuticals and Healthcare Report Q4 2010 Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Romania Pharmaceuticals and Healthcare Report Q4 2010
Product Formats
Please select the product formats and the quantity you require.
Digital Copy--USD 530.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Romania Pharmaceuticals and Healthcare Report Q4 2010 Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Romania Pharmaceuticals and Healthcare Report Q4 2010 Page 5/5